GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (STU:YDO1) » Definitions » Total Noninterest Expense

Madrigal Pharmaceuticals (STU:YDO1) Total Noninterest Expense


View and export this data going back to 2016. Start your Free Trial

Total Noninterest Expense only applies to banks.


Madrigal Pharmaceuticals (STU:YDO1) Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.